BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 38614971)

  • 1. A novel biopsy scheme for prostate cancer: targeted and regional systematic biopsy.
    He Y; Fan Y; Song H; Shen Q; Ruan M; Chen Y; Li D; Li X; Liu Y; Zhang K; Zhang Q
    BMC Urol; 2024 Apr; 24(1):85. PubMed ID: 38614971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimized grade group for reporting prostate cancer grade in systematic and MRI-targeted biopsies.
    He Y; Shen Q; Fu W; Wang H; Song G
    Prostate; 2022 Aug; 82(11):1125-1132. PubMed ID: 35538399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathological findings at radical prostatectomy of biopsy naïve men diagnosed with MRI targeted biopsy alone without concomitant standard systematic sampling.
    Luzzago S; Petralia G; Maresca D; Sabatini I; Cordima G; Brescia A; Verweij F; Garelli G; Mistretta FA; Cioffi A; Pricolo P; Alessi S; Ferro M; Matei DV; Renne G; de Cobelli O; Musi G
    Urol Oncol; 2020 Dec; 38(12):929.e11-929.e19. PubMed ID: 32600928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is Additional Systematic Biopsy Necessary in All Initial Prostate Biopsy Patients With Abnormal MRI?
    Cheng X; Xu J; Chen Y; Liu Z; Sun G; Yang L; Yao J; Zeng H; Song B
    Front Oncol; 2021; 11():643051. PubMed ID: 33718240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can fewer transperineal systematic biopsy cores have the same prostate cancer detection rate as of magnetic resonance imaging/ultrasound fusion biopsy?
    Liu H; Ruan M; Wang H; Wang H; Li X; Song G
    Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):589-595. PubMed ID: 32719353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensive sampling of the umbra and penumbra improves clinically significant prostate cancer detection and reduces risk of grade group upgrading at radical prostatectomy.
    Lee AYM; Chen K; Cheng CWS; Ho HSS; Yuen JSP; Ngo NT; Law YM; Tay KJ
    World J Urol; 2023 Aug; 41(8):2265-2271. PubMed ID: 37395756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel sampling scheme with reduced cores in men with multiparametric MRI-visible lesions undergoing prostate biopsy.
    Ruan M; Wang H; Li X; Song G
    Abdom Radiol (NY); 2023 Jun; 48(6):2139-2147. PubMed ID: 37036488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MRI-targeted or systematic random biopsies for prostate cancer diagnosis in biopsy naïve patients: follow-up of a PRECISION trial-like retrospective cohort.
    Luzzago S; de Cobelli O; Mistretta FA; Piccinelli ML; Lorusso V; Morelli M; Bianchi R; Catellani M; Cozzi G; Di Trapani E; Pricolo P; Alessi S; Ferro M; Marvaso G; Matei DV; Jereczek-Fossa BA; Petralia G; Musi G
    Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):406-413. PubMed ID: 32989259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathological features of Prostate Imaging Reporting and Data System (PI-RADS) 3 MRI lesions in biopsy and radical prostatectomy specimens.
    Rahota RG; Diamand R; Malavaud B; Fiard G; Descotes JL; Peltier A; Beauval JB; Roumeguère T; Roumiguié M; Albisinni S; Ploussard G
    BJU Int; 2022 May; 129(5):621-626. PubMed ID: 34358405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic performance of transperineal prostate targeted biopsy alone according to the PI-RADS score based on bi-parametric magnetic resonance imaging.
    Noh TI; Shim JS; Kang SH; Cheon J; Kang SG
    Front Oncol; 2023; 13():1142022. PubMed ID: 37035173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted multiparametric magnetic resonance imaging/transrectal ultrasound-guided (mpMRI/TRUS) fusion prostate biopsy versus systematic random prostate biopsy: A comparative real-life study.
    Pham THN; Schulze-Hagen MF; Rahnama'i MS
    Cancer Rep (Hoboken); 2024 Feb; 7(2):e1962. PubMed ID: 38217298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining targeted and systematic prostate biopsy improves prostate cancer detection and correlation with the whole mount histopathology in biopsy naïve and previous negative biopsy patients.
    Mischinger J; Schöllnast H; Zurl H; Geyer M; Fischereder K; Adelsmayr G; Igrec J; Fritz G; Merdzo-Hörmann M; Elstner J; Schmid J; Triebl A; Trimmel V; Reiter C; Steiner J; Rosenlechner D; Seles M; Pichler GP; Pichler M; Riedl J; Schöpfer-Schwab S; Strobl J; Hutterer GC; Zigeuner R; Pummer K; Augustin H; Ahyai S; Mannweiler S; Fuchsjäger M; Talakic E
    Front Surg; 2022; 9():1013389. PubMed ID: 36277287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of systematic, MRI-targeted biopsies alone or in combination for the prediction of unfavourable disease in MRI-positive low-risk prostate cancer patients eligible for active surveillance.
    Ploussard G; Beauval JB; Lesourd M; Almeras C; Assoun J; Aziza R; Gautier JR; Loison G; Portalez D; Salin A; Tollon C; Soulié M; Malavaud B; Roumiguié M
    World J Urol; 2020 Mar; 38(3):663-671. PubMed ID: 31197523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Targeted Biopsy and Combined Biopsy to Avoid Unnecessary Systematic Biopsy in Patients with PI-RADS 5 Lesions.
    Yuan C; Li D; Wu J; Shen Q; Wang X; Xiao J; He Z; Zhou L; Li X; Liu Y; Zhao Z
    Biomedicines; 2023 Nov; 11(12):. PubMed ID: 38137384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is There Still a Need for Repeated Systematic Biopsies in Patients with Previous Negative Biopsies in the Era of Magnetic Resonance Imaging-targeted Biopsies of the Prostate?
    Exterkate L; Wegelin O; Barentsz JO; van der Leest MG; Kummer JA; Vreuls W; de Bruin PC; Bosch JLHR; van Melick HHE; Somford DM
    Eur Urol Oncol; 2020 Apr; 3(2):216-223. PubMed ID: 31239236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current role of systematic biopsy in diagnosis of clinically significant prostate cancer in primary combined MRI-targeted biopsy: a high-volume single-center study.
    Krausewitz P; Fostitsch D; Weiten R; Kluemper N; Stein J; Luetkens J; Kristiansen G; Ellinger J; Ritter M
    World J Urol; 2023 Jan; 41(1):19-25. PubMed ID: 36477403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinically significant prostate cancer (csPCa) detection with various prostate sampling schemes based on different csPCa definitions.
    Wang F; Chen T; Wang M; Chen H; Wang C; Liu P; Liu S; Luo J; Ma Q; Xu L
    BMC Urol; 2021 Dec; 21(1):183. PubMed ID: 34949183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Diagnostic efficacy of prostate cancer using targeted biopsy with 6-core systematic biopsy for patients with PI-RADS 5].
    Liu Y; Yuan CW; Wu JY; Shen Q; Xiao JX; Zhao Z; Wang XY; Li XS; He ZS; Zhou LQ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Oct; 55(5):812-817. PubMed ID: 37807733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective analysis of clinically significant prostate cancer detection with [
    Bodar YJL; Zwezerijnen BGJC; van der Voorn PJ; Jansen BHE; Smit RS; Kol SQ; Meijer D; de Bie K; Yaqub M; Windhorst BAD; Hendrikse HNH; Vis AN; Oprea-Lager DE
    Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1731-1742. PubMed ID: 34725727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gleason Grade Group Concordance between Systematic Template Combining Magnetic Resonance Imaging Fusion Targeted Biopsy and Radical Prostatectomy Specimens: A Comparison of Transperineal and Transrectal Approaches.
    Wu S; Feldman AS; Kim MM; Lin SX; Cornejo KM; Harisinghani MG; Dahl DM; Wu CL
    Urology; 2023 May; 175():151-156. PubMed ID: 36828261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.